Qaytarish

Eritropoetin (EPO)

Kod:12017|CPT:82668|LOINC:15061-5

Sinonimlar
Эпостимэпоэтинрекормонрегулятор эритропоэзаEPOEpoetinEpostimErythropoetinErythropoiesis regulatorErythropoietinRecormon
KabiEritropoetin

Tahlil ma'lumotlari

Tadqiqot usuli

  • Immunokimyoluminometrik analiz (ICMA)
  • Ferment immunoanalizi (EIA)

Kutilayotgan natija topshirish vaqti

1–2 kun

Maxsus tayyorlik

  • For children 1–5 years old, withhold food for 2–3 hours before blood draw.
  • Adults should fast for 8 hours prior to collection; water is permitted.
  • Avoid strenuous activity and minimize emotional stress for at least 30 minutes before collection.
  • Do not smoke or use tobacco within 30 minutes before the sample is taken.

Qanday foydalanish

Eritropoetin (EPO) testi, epoetin yoki eritropoetin gormon darajasi deb ham ataladi, aylanayotgan EPO ni anemiya yoki politsitemiyaning darajasi bilan taqqoslash orqali anemiya va eritrotsitozning diagnostik bahosini qo‘llab-quvvatlaydi. U suyak iligi supressiyasi tufayli anemiyani endogen EPO yetishmovchiligi sababli anemiyadan farqlashga yordam beradi va surunkali buyrak kasalligida buyrakning EPO sekretsion quvvatini baholashda qo‘llanadi. Politsitemiyali bemorlarda test noadekvat ravishda oshgan EPO bilan qo‘zg‘atiladigan ikkilamchi sabablarni aniqlashga yordam beradi. Natijalar, shuningdek, anemiyani rekombinant eritropoetin bilan davolashga klinik javobni oldindan baholash va kuzatish uchun ishlatilishi mumkin.

Cheklovlar

Eritropoetin to‘qima gipoksiyasiga javoban ajraladi va eritropoezni oshirish uchun suyak iligini rag‘batlantiradi. Yetarli miqdorda qizil qon hujayralari ishlab chiqarilishi uchun funksional suyak iligi, temir, vitamin B12 va folatning yetarli zaxiralari, eritropoetinning mos darajalari hamda suyak iligining ushbu gormonga javobchanligi zarur. Aylanuvchi eritropoetinning faolligi o‘tkinchi bo‘lib, kislorod yetkazilishi yaxshilanganda kamayadi; buyrakda sintezning kamayishi yoki suyak iligining javobining buzilishi anemiya ko‘rinishida namoyon bo‘lishi mumkin. Aksincha, eritropoetinning ortiqcha ishlab chiqarilishi, jumladan buyrak yoki boshqa o‘smalardan, qon hajmining kengayishi va yopishqoqligining ortishi bilan kechuvchi ikkilamchi politsitemiyaga olib kelishi mumkin. Eritropoetin sutkalik tebranishni namoyon etadi va baland tog‘li hududlarda konsentratsiyalari yuqoriroq bo‘lishi mumkin.

O'lchov birligimIU/mL
Referens oraliq—
Ko'rsatmalarAnemia of unclear cause after excluding iron deficiency, vitamin B12 and folate deficiency, hemolysis, and blood loss, Anemia with reduced red blood cell count, hemoglobin, and hematocrit accompanied by a normal or low reticulocyte count, Differentiation of anemia from bone marrow suppression versus anemia from inadequate endogenous erythropoietin, Determination of erythropoietin production in chronic kidney disease, Workup of polycythemia/erythrocytosis for secondary etiologies related to excess erythropoietin

Natija og'ishlarining mumkin sabablari

Oshgan daraja

  • anabolic steroids
  • erythropoietin therapy
  • high altitude
  • pregnancy

Pasaygan daraja

  • acquired immunodeficiency syndrome
  • blood transfusion
  • cancer
  • enalapril
  • increased plasma viscosity
  • premature neonates
  • rheumatoid arthritis
  • sickle cell disease
  • ulcerative colitis

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm0.5 mL (min 0.3 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Erythropoietin Reaches the Pharmacy. Lancet. 1989 Nov 25; 2(8674):1252-1254 (editorial). PubMed 2573763

Eschbach JW, Adamson JW. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug; 14(2 Suppl 1):2-8. PubMed 2667349

Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med. 1989 Nov 23; 321(21):1449-1459. PubMed 2682244

Hubbard JD, Wheeler DJ. Erythropoietin measurement by EIA. Lab Med. 1989; 20:849-854.

Johnson GR. Erythropoietin. Br Med Bull. 1989; 45(2):506-514. PubMed 2688815

Jones EH. Recombinant human erythropoietin. Am J Hosp Pharm. 1989 Nov; 46(11 Suppl 2):S20-S23. PubMed 2690606

Paganini EP, Latham D, Abdulhadi M. Practical considerations of recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug; 14(2 Suppl 1):19-25. PubMed 2667348

Spivak JL. Erythropoietin. Blood Rev. 1989 Jun; 3(2):130-135. PubMed 2673445

Zanjani ED, Ascensão JL. Erythropoietin. Transfusion. 1989 Jan; 29(1):46-57. PubMed 2643210